PostEra
Medicinal Chemistry powered by Machine Learning
Y CombinatorWinter 2020ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryMachine LearningCOVID-19
What they do
Problem
Drug discovery and medicinal chemistry are slow and expensive, delaying the development of new small-molecule medicines.
Solution
PostEra uses machine learning to accelerate medicinal chemistry and advance small-molecule drug programs via a platform used in partnerships and its internal pipeline.
Who it's for
Biopharma companies and drug discovery organizations developing small-molecule therapeutics.
Founders
Aaron Morris
Founder
CEO at PostEra
Alpha Lee
Founder
Matthew Robinson
Founder
Open roles 1
Lead Software Engineer, Platform
Company timeline
- Founded2019
- YC batchWinter 2020
- StatusActive
- Team size40 people
- LocationBoston, MA, USA
Similar startups
Enjamb Labs
Full stack AI Agents accelerating Biopharma R&D
Cellbyte
AI Agents for Pharma Drug Launches
Lavo Life Sciences
AI for drug formulation
Genesis Molecular AI
Foundation models and AI operating system for small molecule drug dis…
Xaira
Xaira is reinventing drug R&D using artificial intelligence to rapidl…
Inceptive
Foundation models for molecule design, customized for partners to ena…